MSLE logo

Satellos Bioscience Inc.

MSLE
Healthcare|Biotechnology|CA
$7.19
+0.84 (+13.23%)
DCF Value
$4.97
Tangible Book / Share
$2.87
Cash / Share
$2.96
Next Earnings Report
Nov 13, 2026
EPS est. -$0.60
Financing Filings (last 12 months)
1
Shelf registrations / offering prospectuses — latest Aug 11, 2026 (F-10). Possible dilution.

Upcoming Data Readouts (1)

Mar 2027
Est. completion
P2Duchenne Muscular Dystrophy
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
NCT07287189n=51

SEC Filings (15)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 6, 20266-KForeign issuer reportDocumentIndex
Nov 5, 20266-KForeign issuer reportDocumentIndex
Oct 27, 20266-KForeign issuer reportDocumentIndex
Oct 21, 20266-KForeign issuer reportDocumentIndex
Oct 5, 20266-KForeign issuer reportDocumentIndex
Sep 30, 20266-KForeign issuer reportDocumentIndex
Sep 24, 20266-KForeign issuer reportDocumentIndex
Sep 15, 20266-KForeign issuer reportDocumentIndex
Sep 9, 20266-KForeign issuer reportDocumentIndex
Sep 1, 20266-KForeign issuer reportDocumentIndex
Aug 14, 20266-KForeign issuer reportDocumentIndex
Aug 14, 2026SUPPLDocumentIndex
Aug 13, 20266-KForeign issuer reportDocumentIndex
Aug 11, 2026F-XDocumentIndex
Aug 11, 2026F-10IPO / offering registrationDocumentIndex